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Summary The expression of c-myc was studied in 51 malignant lymphomas and in a variety of normal
tissues by immunocytochemistry using monoclonal antibodies raised to different synthetic peptides and
reacting monospecifically with the c-myc product (p62C-Yc). The c-myc product was detected in only a
minority of malignant lymphomas principally those containing cells with immunoblastic characteristics, and
was predominantly localised to the cytoplasm. In normal lymphoid tissues only plasma cells and histiocytes
were found to have immunoreactivity. In non-lymphoid normal tissues, however, the c-myc product was
distributed widely. Marked differences in its intracellular distribution were apparent in different tissues. These
findings suggest that the relationship of p62c-lYc expression to cell division may be more complex than
previously suggested by in vitro studies, and raise the possibility that it may have other functions within the
cell.
The human c-myc proto-oncogene is a cellular gene
homologous with the 3' sequence of the transform-
ing gene of the avian myelocytomatosis virus MC29
(Papas et al., 1984). It has been shown that in
Burkitt lymphoma-derived cell lines the c-myc
proto-oncogene is often involved in reciprocal
translocations involving the immunoglobulin genes
although the chromosomal break points may differ
(Gellmann et al., 1983; Erikson et al., 1983;
Hayday et al., 1984); in some circumstances this
appears to be associated with mutation of c-myc
(Rabbitts et al., 1983). This type of rearrangement
has also been described in murine plasmocytoma
cell lines (Bernard et al., 1983). Rearrangement of
c-myc has also been described in cell lines or fresh
tissue from other lymphoid tumours, but these are
less well characterised in terms of the precise
genomic configuration (Rothberg et al., 1984;
Dalla-Favera et al., 1983). Rearrangements of the
c-myc proto-oncogene have been correlated with
elevated expression but this does not appear to be
invariably the case (Klein, 1981; Hamlyn &
Rabbitts, 1983). In some Burkitt cell lines levels of
c-myc mRNA comparable to those seen in normal
cells are found, but the untranslocated allele is
silent (Taub et al., 1984). This raises the possibility
that the translocation may result in expression at an
inappropriate stage of cellular development. On the
basis of this work, it has been suggested that
J.C.-B
abnormal expression of c-myc may be critically
involved in development of lymphomas.
In contrast to the extensive study of Burkitt
lymphoma derived cell lines there is little known
about the expression of this gene in other types of
lymphoid tumour or in normal lymphoid tissues.
Elevated levels of c-myc mRNA have been found in
some tumours (Rothberg et al., 1984; Roy-Burnam
et al., 1983; Slamon et al., 1984), but the interpreta-
tion of these results is complicated by the extensive
cellular heterogeneity which may be present in
malignant lymphomas.
We therefore decided to investigate c-myc
expression in lymphoid tumours using monoclonal
antibodies to the p62c-mYc gene product. It was
hoped that such an immunocytochemical study
would give information about the cellular distribu-
tion of the c-myc product in both normal and
malignant lymphoid tissue and the relationship of
c-myc expression, if any, to cellular differentiation.
It was hoped that it would be possible to comment
on whether the gene was being aberrantly or
constitutively expressed in tumour cells.
Materials and methods
Tissue
Tissue was obtained from 51 lymphoid tumours
including most histological types commonly seen
and 20 examples of normal lymphoid tissue (lymph
node, spleen, thymus, tonsil and bone marrow).
With the exception of two cases originating in East
Africa all were recent biopsy specimens from
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Glasgow Royal Infirmary. All tissue was fixed in
buffered formol saline and embedded in paraffin
wax.
The diagnosis was made on the basis of routine
histology and a wide variety of immunocyto-
chemical tests. The diagnostic categories broadly
follow those described in the Kiel classification or
the Lukes-Butler classification of Hodgkin's disease
(Wright & Isaacson, 1983; Lukes & Butler, 1966).
Monoclonal antibodies
Two monoclonal antibodies were used. These were
raised against synthetic peptides as previously
described. The antibodies designated myc-I 6E10
and myc-I 9E10 have been shown to react with
different regions of the p62c-mYc molecule and to be
monospecific on immunoblotting with various cell
lines (Evan et al., 1985). Myc-I 9E10 was in the
form of a purified antibody (2mgml-1) and was
used as a dilution of 1/500 in Tris buffer pH 7.6.
Myc-l 6E10 was in the form of hybridoma super-
natant and was diluted to 1/20. These concentra-
tions were obtained after titration studies on
normal and neoplastic tissue.
Immunocytochemistry
Tissue sections were dewaxed and hydrated. All
sections were routinely trypsinised for 5-15min.
Endogenous peroxidase activity was blocked using
acidified methanol containing hydrogen peroxide.
After washing in Tris saline, pH 7.6, sections were
incubated overnight with diluted primary antibody
at 20°C. The sections were washed and incubated
for 30 min with optimally diluted rabbit anti-mouse-
horseradish peroxidase conjugate (Dako). Antibody
binding was demonstrated by immersion in di-
aminobenzidine and hydrogen peroxide for 10min.
Sections were then washed, counterstained with
haematoxylin and dehydrated. A control section
was stained, for each specimen, omitting the
primary antiserum.
Results
Antibody specificity
An identical pattern of staining was obtained using
both monoclonal antibodies. (Figure la,b). As
these were raised to different parts of the p62c-mYc
molecule it renders fortuitous cross reactions,
commonly seen with monoclonal antibodies,
unlikely.
Distribution ofstaining
Normal lymphoid tissue All lymphoid cells seen in
normal lymph node, spleen, tonsil and thymus were
unstained with the exception of plasma cells (see
Table I). (Figure 2). These cells showed marked
and consistent cytoplasmic staining. In thymus
strong granular cytoplasmic staining was present in
the epithelial cells including Hassall's corpuscles. In
tonsil granular cytoplasmic staining was present in
crypt epithelium. In both spleen and lymph node
rather faint cytoplasmic staining was seen in histio-
cytes. This was most marked in the tingeable body
histiocytes associated with germinal centres.
Intense nuclear and cytoplasmic staining was
present in the majority of haemopoietic precursor
cells seen in normal bone marrow (Figure la,b).
Weak cytoplasmic staining was sometimes seen in
mature granulocytes.
Lymphoid tumours A summary of the staining
patterns found in lymphoid tumours is given in
Table II. A number of additional points should be
noted. Two lymphoblastic tumours were included.
Table I C-myc in normal lymphoid and haemopoietic tissue
Tissue Distribution ofstaining with anti-p62c myC
Lymph node (a) Granular cytoplasmic staining in some
histocytes, especially those in germinal centres.
(b) Cytoplasmic staining ofmost plasma cells. All
other lymphoid cells are negative.
Spleen (a) Weak cytoplasmic staining in some sinus lining
cells.
(b) White pulp negative except plasma cells.
Thymus (a) Strong granular staining ofepithelial elements.
(b) All lymphoid cells are negative.
Bone marrow (a) Intense nuclear and cytoplasmic staining in all
stages in differentiation.
(b) Weak cytoplasmic staining in mature
granulocytes.C-MYC ONCOGENE PRODUCT IN LYMPHOMAS AND NORMAL TISSUES
Figure 1 Normal bone marrow. (a) Monoclonal antibody 9E10; (b) monoclonal antibody 6E10; A similar
distribution is seen with both antibodies. Nuclear and cytoplasmic immunostaining is present in myeloid and
erythroid precursor cells and megakaryocytes. ( x 128)
Table II C-myc in lymphoid tumours
Number
Tumour type staining +ve Comments
B-lymphocytic/lympho- 1/2 Faint positive staining in some
plasmacytic cells of the lymphoplasmacytic
tumour.
B-lymphoblast (including 1/2 Staining mainly cytoplasmic.
BI)
Follicle centre cell tumours 3/17 Positive staining very weak
restricted to the cytoplasm of
B-immunoblast 0/1 cells.
T-lymphocytic 0/2
T-lymphoblastic 0/2
Pleomorphic peripheral T 2/6 Positive staining (nuclear +
cell tumour cytoplasmic) restricted to
immunoblast and multilobated
elements.
T-immunoblastic 5/5 Variable cytoplasmic staining with
occasional nuclei stained.
Hodgkin's disease 7/12 Positive staining present in
variable numbers of Reed-
Sternberg cells.
Plasma cell tumours 2/2 Cytoplasmic staining similar to
normal plasma cells.
One of these was a typical example of African
Burkitt lymphoma (BL), which showed minimal
staining of tumour cells but a moderate degree of
staining of the substantial component of reactive
histiocytes (Figure 3). The other case which differed
morphologically from BL showed weak cytoplasmic
staining. Positive staining was seen in all T-
immunoblastic malignant lymphomas although in
some cases this was rather weak. Some cells in
these tumours showed nuclear as well as cyto-
plasmic staining.
In addition, large cell elements, presumably
immunoblasts, were found to be stained in two
cases of pleomorphic peripheral T cell tumours
(Figure 4), although most of the small or intermedi-
ate sized cells were unstained (Figure 5). Two
plasma cell tumours showed diffuse cytoplasmic
and, occasionally nuclear staining of the type seen
in normal plasma cells.
In the cases of Hodgkin's disease some Reed-
Sternberg cells showed cytoplasmic and occasion-
ally nuclear staining, although this was variable
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Figure 2 Gastric mucosa. This is a section of gastric
mucosa who shows changes of chronic superficial
gastritis. There is promient immunostaining of the
cytoplasm of lamina propria plasma cells. The gastric
surface epithelial cells are also positively stained. This
was a feature of epithelial cells at all levels in the
gastric glands. ( x 160)
Figure 3 Burkitt lymphoma. There is staining of large
inclusions within the cytoplasm of the reactive 'starry
sky' histiocytes. Most of the tumour cells are
unstained although a few cells show a very faint
degree of positivity which is difficult to distinguish
from background staining. (x 120)
Figure 4 Pleomorphic T cell lymphoma. This tumour
contains a wide variety of types of neoplastic cell. The
cells which are stained most prominently with the anti-
p62C-m are the large immunoblast-like cells. In these
cells both the nucleus and cytoplasm are stained.
( x 160)
Figure 5 Pleomorphic T cell lymphoma in liver. This
section shows intense infiltration of a portal tract by
neoplastic lymphoid cells. Cytoplasmic immuno-
reactivity is present in residual bile duct epithelium but
there is no definite staining of tumour cells. (x 160)
Figure 6 Follicle centre cell lymphoma in jejunum.
These sections show diffuse infiltration of the lamina
propria of the jejunum by neoplastic lymphoid cells.
Granular immunostaining is present localised to the
cytoplasm of the intestinal glandular epithelium. The
tumour cells are not stained. Similar staining was seen
at all levels of the small intestinal crypt and villous
epithelium. (x 108)
even within individual cases. Positively staining
Reed-Stemnberg cells were seen in lymphocyte pre-
dominant nodular, nodular sclerosis and mixed
cellularity subtypes of Hodgkin's disease.
Normal non-lymphoid tissues Non-lymphoid cells
were often present in biopsies of lymphoid tissue.
As shown in Table III, a wide variety of cell types
showed immunoreactivity. Some cells, such as con-
nective tissue cells, showed diffuse cytoplasmic
staining, similar to that seen in plasma cells. In
other cells, notably hepatocytes and jejunal
epithelium, (Figure 6) p62c-myc was localised to
coarse, intensely staining cytoplasmic granules. The
perinuclear distribution of these granules in entero-
cytes suggested an association with the Golgi
apparatus.C-MYC ONCOGENE PRODUCT IN LYMPHOMAS AND NORMAL TISSUES
Table III C-myc in normal non-lymphoid tissues
Distribution ofstaining with anti-p62c'tYc
Epidermis and other
squamous epithelia
Small intestine
Liver
Salivary gland
Thyroid
Connective tissues
Stomach
Discussion
The aim of this study was to determine whether
p62C-mYc was detectable in normal lymphoid tissues
and tumours by immunocytochemical methods and
whether this was related to cellular differentiation.
Twenty-one of 51 cases of malignant lymphoma
showed some evidence of immunocytochemical
reactivity with the anti p62c-myc monoclonal anti-
bodies. However, in the majority of cases, especially
follicle centre cell tumours, the intensity of staining
was very weak relative to that seen in some normal
tissues. Nevertheless some tentative conclusions can
be drawn about the relationship of anti p62c-mYc
staining and cellular differentiation.
Positive staining was most consistent in T
immunoblastic malignant lymphomas and this was
further corroborated by the positive immuno-
reactivity in the immunoblast component of pleo-
morphic peripheral T cell tumours. It was of
interest that many Reed-Sternberg cells in cases of
Hodgkin's disease also stained positively; some
authors hold the view that these cells are modified
immunoblasts, in most cases of the T cell type
(Stein et al., 1984). It was not possible to determine
whether normal T-immunoblasts contained p62c-mYc
since these cells are rarely seen in normal lymphoid
tissue and suitable material from cases of reactive T
immunoblastic hyperplasia such as infective mono-
nucleosis was not available. Therefore it is
impossible to comment on whether the tumour cells
are aberrantly expressing the c-myc gene product.
Two cases of lymphoblastic malignant lymphoma
were studied, one of which was a typical African
BL. The latter case showed no definite evidence of
tumour cell reactivity, but there was intense
Granular cytoplasmic staining mainly in basal
layer.
Granular perinuclear staining in both crypts and
villous epithelium.
Granular cytoplasmic staining in hepatocytes and
bile duct epithelium.
Cytoplasmic staining in ducts. Salivary acini are
negative.
Granular cytoplasmic staining in thyroid acinar
cells.
Cytoplasmic staining in both smooth and skeletal
muscle. Weaker staining in other mesenchymal cells
including adipocytes, fibroblasts and endothelium.
Diffuse cytoplasmic staining of gastric antral
epithelium.
granular staining in the reactive histiocytes which
are a prominent feature of this condition. The non-
Burkett B-lymphoblastic malignant lymphoma
showed weak cytoplasmic staining. Again no
equivalent normal cell type could be studied as
those cells are not identifiable in normal tissues.
In cultured lymphoid cells a transient increase in
levels of c-myc mRNA is found after mitogen or
growth factor stimulation at the GO/G1 transition
(Kelly et al., 1984). As transcription in some
systems does not appear to vary during the cell
cycle, regulation of c-myc mRNA may be partly
related to variable rates of degradation (Blanchard
et al., 1985). In a wide range of other cells c-myc is
induced in early G1 phase and persists during S and
G2 phases of the cell cycle (Rabbitts et al., 1985).
Our results are not consistent with a simple
relationship of p62c-mYc expression and cell division.
Positive immunoreactivity was seen in a wide range
of cells, including terminally differentiated cells
such as plasma cells and skeletal muscle cells as
well as dividing cells such as haemopoietic marrow
and Go arrested cells such as hepatocytes. Immuno-
reactive c-myc product has been described in
normal testicular cells (Sikora et al., 1985). An
imperfect correlation with cell division and c-myc
mRNA expression has also been found using in situ
hybridisation of human embryos (Pheifer-Ohlsonn
et al., 1984). One possible explanation for the
discrepancy between our results and the various in
vitro studies could lie in the intracellular dis-
tribution of p62c-mYc. In cultured cells c-myc gene
product is of short half life and localised to the
nucleus (Rabbits et al., 1985). In this study a
nuclear distribution was seen in the actively
dividing cells of bone marrow and in some
Tissue
717718 A.S. JACK et al.
tumours. However, in most normal cells which
show immunoreactivity the localisation of p62c-PyC
was cytoplasmic. The pattern of staining of entero-
cytes and hepatocytes suggests that in these cells
the protein was probably concentrated in the Golgi
apparatus. This suggests that localisation of the
protein, in vivo, may differ in cells which are
dividing as opposed to those which are arrested or
terminally differentiated.
In view of the unexpected results of this study
the possibility of antibody cross-reactivity must
obviously be considered. This is a serious problem
when using single monoclonal antibodies. (Nigg et
al., 1982). However, in this study antibodies to
separate parts of the p62c-myc were used and taken
with the detailed characterisation of these anti-
bodies, cross-reactivity would seem to be a highly
unlikely explanation. The second problem lies in
the sensitivity of the methods used. Immunohisto-
chemical methods are known to be very sensitive
but nevertheless it cannot be definitively stated that
very low levels of p62c-mYc may not be detected and
that these could have biological significance.
Tissues were fixed rapidly after removal from the
patient which therefore makes it unlikely that c-myc
protein would have been significantly catabolised
before fixation. A further possibility is that the
intracellular distribution of p62c-myc was altered by
fixation, either by diffusion, or some other
mechanism. However, it is difficult to envisage how
the observed tissue-specific differences in distribu-
tion could be accounted for by this type of artefact.
Furthermore, the intense granular localisation seen
in some cells (Figures 5 and 6) would not be
consistent with fixation associated diffusion.
In conclusion, our study provides little evidence
to support the view that elevated expression of c-
myc is a common or necessary feature of Ihuimian
malignant lymphomas. Widespread distribution of
this protein in normal tissues raises a number of
interesting questions concerning its function. These
concern the possible differing functions of nuclear
and cytoplasmic p62c-myc since it may be that one is
active and the other a storage form of the molecule.
It would also be relevant to ask whether c-myc is
involved solely in the control of cell division or
whether it participates in other aspects of cellular
metabolism. These questions clearly merit further
investigation. Finally, it does not appear that the
immunocytochemical demonstration of p62c-mYc is of
value in the pathological diagnosis or subtyping of
malignant lymphomas.
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